Noteworthy Friday Option Activity: CTLP, SOUN, TEM
SoundHound AI Inc Options Trading: SoundHound AI Inc (SOUN) experienced significant options trading with 621,536 contracts, notably the $14 strike call option expiring August 08, 2025, which saw 36,946 contracts traded.
Tempus AI Inc Options Trading: Tempus AI Inc (TEM) also had high options trading volume of 136,045 contracts, particularly for the $62 strike call option expiring August 08, 2025, with 17,503 contracts traded.
Trade with 70% Backtested Accuracy
Analyst Views on TEM
About TEM
About the author
Tempus AI Shares Approach 1-Year Low as Cathie Wood’s ARK Increases Holdings While Selling Nvidia, Meta, and Other Tech Stocks
ARK Investment Management's Activity: ARK Investment Management has purchased more shares of Tempus this week, investing nearly $28 million in the company despite its stock hitting a one-year low. The firm has also reduced its stakes in several large tech holdings.
Tempus' Recent Developments: Tempus has expanded its role in precision oncology research and clinical trial optimization, partnering with major pharmaceutical companies like Daiichi Sankyo to develop new cancer therapies using AI technology.
Market Sentiment and Stock Performance: Despite a recent decline in Tempus' stock, analysts maintain a positive outlook, with several firms reiterating 'buy' ratings and projecting significant revenue growth for the company in the coming years.
Retail Investor Sentiment: Retail sentiment towards Tempus has shifted to a more cautious stance, with some investors expressing optimism about future growth opportunities, while the stock has seen a significant decline over the past year.
Tempus AI (TEM.US) Executive Plans to Sell $7.77 Million in Common Stock via Form 144
Stock Sale Announcement: Eric Lefkofsky intends to sell 166,250 shares of his common stock in Tempus AI (TEMS), valued at approximately $7.77 million.
Reduction in Holdings: Since January 28, 2026, Lefkofsky has reduced his shareholding in Tempus AI by 346,090 shares, with a total value of around $21.49 million.
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
TEMPUS AI STOCK RISES 2% IN PREMARKET TRADING FOLLOWING COLLABORATION WITH DAIICHI SANKYO ON CANCER TREATMENT
Market Reaction: Tempus AI shares increased by 2% in pre-market trading.
Partnership Announcement: The rise in shares follows a partnership with Daiichi Sankyo focused on cancer drug development.
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
Tempus AI Shares Approach 1-Year Low as Cathie Wood’s ARK Increases Holdings While Selling Nvidia, Meta, and Other Tech Stocks
ARK Investment Management's Activity: ARK Investment Management has purchased more shares of Tempus this week, investing nearly $28 million in the company despite its stock hitting a one-year low. The firm has also reduced its stakes in several large tech holdings.
Tempus' Recent Developments: Tempus has expanded its role in precision oncology research and clinical trial optimization, partnering with major pharmaceutical companies like Daiichi Sankyo to develop new cancer therapies using AI technology.
Market Sentiment and Stock Performance: Despite a recent decline in Tempus' stock, analysts maintain a positive outlook, with several firms reiterating 'buy' ratings and projecting significant revenue growth for the company in the coming years.
Retail Investor Sentiment: Retail sentiment towards Tempus has shifted to a more cautious stance, with some investors expressing optimism about future growth opportunities, while the stock has seen a significant decline over the past year.
Tempus AI (TEM.US) Executive Plans to Sell $7.77 Million in Common Stock via Form 144
Stock Sale Announcement: Eric Lefkofsky intends to sell 166,250 shares of his common stock in Tempus AI (TEMS), valued at approximately $7.77 million.
Reduction in Holdings: Since January 28, 2026, Lefkofsky has reduced his shareholding in Tempus AI by 346,090 shares, with a total value of around $21.49 million.
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
TEMPUS AI STOCK RISES 2% IN PREMARKET TRADING FOLLOWING COLLABORATION WITH DAIICHI SANKYO ON CANCER TREATMENT
Market Reaction: Tempus AI shares increased by 2% in pre-market trading.
Partnership Announcement: The rise in shares follows a partnership with Daiichi Sankyo focused on cancer drug development.
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
